India, Jan. 21 -- image credit- freepik

Mumbai-headquartered pharma major Lupin Limited has announced a licensing and supply agreement through its subsidiary Lupin Atlantis Holdings SA (LAHSA) with Spain-based Galenicum Health, S.L.U. for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist.

As per the agreement, Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally, including Canada, Europe, Southeast Asia and Latin America. Lupin is well-positioned to expand its leadership in diabetes care and obesity beyond India with this Semaglutide partnership.

Semaglutide is a ...